Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Morphochem Inc.

Division of Biovertis AG

Latest From Morphochem Inc.

Deal Trends, Part I: No Bridge Over the Drug-Discovery Divide

Platform technology deals were the hot item and the strategic basis for a raft of biotechs. But if their technologies opened some bottlenecks, they've failed to speed up the discovery process significantly. Big Pharma, meanwhile, has cut its technology spending--for a variety of reasons, including the necessity of learning to integrate what they've bought. As a result, platform companies are changing course. Some are becoming product-oriented players; others are repackaging their service offerings to help drug firms finance larger drug discovery programs.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Small Molecule Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Biovertis AG
  • Senior Management
  • Robert J More, COO
    David C Brush, VP, Bus. Dev.
    Krishna Kodukula, PhD, Exec. Dir, Res.
    Eric M Eastman, Pres.
  • Contact Info
  • Morphochem Inc.
    Phone: (732) 274-2882
    11 Deer Park Dr., Ste. 116
    Monmouth Junction, NJ 08852